Meridian Bioscience Israel Ltd is an Israel-based company active in the medical sector. The Company develops, manufactures, and distributes a broad range of diagnostic test kits, reagents, and related products. The Company develops and commercializes advanced systems that extract vital information for diagnostics from subtle changes in the patient's exhaled.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Delayed TEL AVIV STOCK EXCHANGE			5-day change	1st Jan Change
- ^ILa	-.--%		+1.39%	+107.88%

20-04-29	Meridian Bioscience, Inc. completed the acquisition of Exalenz Bioscience Ltd from Mori Arkin and others.	CI
20-02-18	Meridian Bioscience, Inc. agreed to acquire Exalenz Bioscience Ltd from Mori Arkin and others for approximately ILS 170 million.	CI

Market Cap	161M 0 145M 133M 121M 225M 15.33B 229M 1.59B 637M 8.06B 606M 593M 25.43B	P/E 2018	-34.6x	P/E 2019	-40x
Enterprise Value	165M 0 147M 136M 123M 230M 15.62B 234M 1.62B 649M 8.22B 618M 604M 25.92B	EV / Sales 2018	15.2x	EV / Sales 2019	5.75x
Free-Float	24.36%	Yield 2018 *	-	Yield 2019	-

20-04-29	Meridian Bioscience, Inc. completed the acquisition of Exalenz Bioscience Ltd from Mori Arkin and others.	CI
20-02-18	Meridian Bioscience, Inc. agreed to acquire Exalenz Bioscience Ltd from Mori Arkin and others for approximately ILS 170 million.	CI
19-08-13	Exalenz Bioscience Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2019	CI
19-02-25	Exalenz Bioscience Receives Approval for Commercial Marketing in China for Its Breathid® HP Lab System	CI
18-11-15	Exalenz Bioscience Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018	CI
18-08-31	Exalenz Bioscience Ltd Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2018	CI
18-07-10	Exalenz Bioscience Ltd. Announces BreathID®13C-methacetin Breath Test	CI
18-04-30	Exalenz Bioscience Appoints Roy Golan as President and Chief Financial Officer	CI
18-03-13	Exalenz Bioscience’s BreathID® Hp & BreathID Hp Lab Systems Receive FDA Clearance for Diagnosis of Helicobacter pylori Testing in Pediatric Patients	CI
18-03-12	Exalenz Bioscience Ltd Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017; Provides Earnings Guidance for the Year 2018 and Revenue Guidance for the Year 2019	CI
18-01-24	Exalenz Bioscience Announces Positive Clinical Trial Results for the Diagnosis of Clinically Significant Portal Hypertension in NASH Patients	CI
17-08-17	Exalenz Bioscience Ltd Launches Automated BreathID® Hp Lab Urea Breath Testing System For Helicobacter pylori Detection	CI
17-08-14	Exalenz Bioscience Plans For Nasdaq IPO	CI

Manager	Title	Age	Since
Moshe Dori DFI	Director of Finance/CFO	-	2019-01-28
Ofer Schlesinger CTO	Chief Tech/Sci/R&D Officer	62	2014-07-22
Eitan Blank COO	Chief Operating Officer	56	2006-12-31

Exalenz Bioscience Ltd Stock

Stocks

EXEN

IL0011048688

Medical Equipment, Supplies & Distribution

Valuation: Exalenz Bioscience Ltd

Latest news: Exalenz Bioscience Ltd

Press Releases: Exalenz Bioscience Ltd

Managers and Directors: Exalenz Bioscience Ltd

Other Medical Equipment, Supplies & Distribution

Financials

Company Profile

Director	Title	Age	Since
Moshe Arkin CHM	Chairman	74	2005-12-31
Itai Arkin BRD	Director/Board Member	37	2015-04-15
Hanna Lerman BRD	Director/Board Member	52	2015-04-15

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EXALENZ BIOSCIENCE LTD	-.--%	+1.39%	-	-	45.97M
ABBOTT LABORATORIES	+1.56%	+2.41%	-14.09%	+12.32%	184B
MEDTRONIC PLC	-0.59%	+1.18%	+6.44%	+36.82%	118B
STRYKER CORPORATION	-6.38%	-4.98%	-18.07%	+8.01%	111B
ESSILORLUXOTTICA	+3.42%	+1.71%	-41.92%	+8.01%	94.58B
CENCORA, INC.	+0.09%	-0.05%	-2.06%	+78.69%	63.13B
HOYA CORPORATION	-0.46%	+0.42%	+4.48%	+82.84%	55.66B
BECTON, DICKINSON AND COMPANY	-0.23%	-0.52%	+10.73%	-21.72%	53.9B
IDEXX LABORATORIES, INC.	-4.30%	-1.64%	-12.44%	+37.99%	43.42B
ALCON INC.	+0.58%	+2.00%	-1.17%	-8.82%	34.68B
Average	-0.63%	+0.19%	-7.57%	+26.01%	75.85B
Weighted average by Cap.	-0.48%	+0.24%	-10.13%	+23.75%

	2018	2019
Net sales	13.14M 0 11.77M 10.83M 9.81M 18.34M 1.25B 18.68M 129M 51.84M 657M 49.33M 48.28M 2.07B	14.04M 0 12.58M 11.57M 10.48M 19.6M 1.33B 19.96M 138M 55.39M 701M 52.71M 51.59M 2.21B
Net income	-5.5M -0 -4.92M -4.53M -4.1M -7.67M -522M -7.81M -54.01M -21.68M -275M -20.63M -20.19M -866M	-1.94M -0 -1.74M -1.6M -1.45M -2.71M -184M -2.76M -19.06M -7.65M -96.9M -7.28M -7.13M -306M
Net Debt	2.93M 0 2.62M 2.41M 2.18M 4.08M 278M 4.16M 28.76M 11.54M 146M 10.98M 10.75M 461M	3.09M 0 2.77M 2.55M 2.31M 4.32M 294M 4.4M 30.39M 12.2M 154M 11.61M 11.36M 487M